(VIANEWS) – The NASDAQ ended the session with Novavax jumping 21.98% to $4.86 on Thursday, after three consecutive sessions in a row of losses. NASDAQ rose 2.96% to $16,041.62, after three successive sessions in a row of losses, on what was an all-around up trend trading session today.
Novavax’s last close was $3.98, 64.96% under its 52-week high of $11.36.
About Novavax
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, Adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also focusing on products candidates for respiratory syncytial virus and malaria. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Earnings Per Share
As for profitability, Novavax has a trailing twelve months EPS of $-6.23.
Volatility
Novavax’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.05%, a negative 0.07%, and a positive 2.92%.
Novavax’s highest amplitude of average volatility was 2.05% (last week), 2.93% (last month), and 2.92% (last quarter).
Yearly Top and Bottom Value
Novavax’s stock is valued at $4.86 at 17:06 EST, way under its 52-week high of $11.36 and way higher than its 52-week low of $3.53.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Novavax’s stock is considered to be overbought (>=80).
Revenue Growth
Year-on-year quarterly revenue growth declined by 74.5%, now sitting on 1.05B for the twelve trailing months.
More news about Novavax (NVAX).
